NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
Clinical Trials
83 trialsNCT04388475 2025-08-12
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
Oblato, Inc.
Phase 2 Completed
NCT04400188 2025-06-29
A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Completed
NCT02667587 2025-06-18
CheckMate548
Bristol-Myers Squibb
Phase 3 Completed
NCT02655601 2025-06-08
BMX-HGG
BioMimetix JV, LLC
Phase 1/2 Completed
NCT03782415 2025-05-21
Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma
MediciNova
Phase 1/2 Completed
NCT03576612 2025-02-14
GMCI
Candel Therapeutics, Inc.
Phase 1 Completed
NCT03150810 2024-12-20
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
BeiGene
Phase 1 Completed
NCT04434482 2024-09-19
IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer
Impact Therapeutics, Inc.
Phase 1/2 Completed
NCT03776071 2024-04-22
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
Denovo Biopharma LLC
Phase 3 Completed
NCT00589875 2024-04-03
BrTK02
Candel Therapeutics, Inc.
Phase 2 Completed
NCT02052648 2024-03-27
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Lumos Pharma
Phase 1/2 Completed
NCT02315534 2023-11-15
A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT01618136 2023-06-18
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT02573324 2023-05-11
Intellance1
AbbVie
Phase 3 Completed
NCT02617589 2023-03-28
CheckMate 498
Bristol-Myers Squibb
Phase 3 Completed
NCT03867123 2023-02-21
A Study to Evaluate the Safety of LAM561 Added to Standard of Care in Newly-diagnosed Glioblastoma Patients
Laminar Pharmaceuticals
Phase 1 Completed
NCT02511132 2022-12-22
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Gradalis, Inc.
Phase 2 Completed
NCT00687765 2022-09-14
Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma
Sanofi
Phase 1/2 Completed
NCT02871843 2022-05-16
G-FORCE-1
EpicentRx, Inc.
Phase 1 Completed
NCT01506609 2021-10-25
Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
AbbVie
Phase 2 Completed
NCT03034135 2021-09-13
Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma
Cantex Pharmaceuticals
Phase 2 Completed
NCT02903069 2021-04-19
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
Celgene
Phase 1 Completed
NCT01473901 2020-12-09
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Novartis
Phase 1 Completed
NCT02698410 2020-10-01
ATLANT
Ipsen
Phase 2 Completed
NCT02590263 2020-09-03
Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
AbbVie
Phase 1/2 Completed
NCT00402116 2020-08-06
Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
Eli Lilly and Company
Phase 1/2 Completed
NCT01390948 2020-08-06
A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma
Hoffmann-La Roche
Phase 2 Completed
NCT01790503 2020-06-30
A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma
Daiichi Sankyo
Phase 1/2 Completed
NCT02502708 2020-06-04
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Lumos Pharma
Phase 1 Completed
NCT02343406 2020-05-22
INTELLANCE-2
AbbVie
Phase 2 Completed
NCT01704287 2020-05-18
KEYNOTE 002
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02799238 2020-04-30
ALECSAT
CytoVac A/S
Phase 2 Completed
NCT02231762 2019-05-06
SONNET
Ipsen
Phase 2 Completed
NCT00977431 2019-02-18
Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
Boehringer Ingelheim
Phase 1 Completed
NCT00804908 2018-06-06
A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma
AbbVie
Phase 2 Completed
NCT01113957 2018-06-06
A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
AbbVie
Phase 2 Completed
NCT01860638 2018-04-30
A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
Hoffmann-La Roche
Phase 2 Completed
NCT00458601 2018-01-16
ACT III
Celldex Therapeutics
Phase 2 Completed
NCT01480479 2018-01-16
ACT IV
Celldex Therapeutics
Phase 3 Completed
NCT00526617 2017-11-21
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
AbbVie
Phase 1 Completed
NCT01085422 2017-11-21
A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
AbbVie
Phase 1 Completed
NCT01800695 2017-11-21
Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme
AbbVie
Phase 1 Completed
NCT00943826 2017-09-25
A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma
Hoffmann-La Roche
Phase 3 Completed
NCT00727506 2017-08-15
BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma
Boehringer Ingelheim
Phase 2 Completed
NCT00686725 2017-06-14
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT00392171 2017-06-07
The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00424554 2017-06-07
Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00684567 2017-06-07
Temozolomide Phase II Clinical Study in Patients With Newly Diagnosed Glioblastoma Multiforme (Study P04661)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00687323 2017-06-07
TALL
Merck Sharp & Dohme LLC
Phase 2 Completed